Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

H3 Pharma licenses SC-1 from OncoMab

March 19, 2003

WX-G250 + low-dose IL-2 safe and active in progressive, metastatic RCC

March 18, 2003

GVAX enhances antitumor immunity in certain patients with advanced NSCLC

March 7, 2003

Aphton presents phase III results for G17DT to foreign regulatory authority

March 7, 2003

Aldara shows benefit in pivotal studies in actinic keratosis and basal cell carcinoma

March 5, 2003

Preliminary results from CpG-7909 proof-of-principle study announced

March 4, 2003

HuMax-CD20 kills rituximab-resistant tumor cells in preclinical studies

Feb. 20, 2003

Phase II interim results for GI7DT plus chemotherapy in gastric cancer

Feb. 13, 2003

Increased survival associated with antitumor T-cell response in ovarian cancer

Feb. 10, 2003

Schering AG acquires Japanese and Asian rights to Campath

Feb. 7, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...